Navigation Links
International Panel of Experts Gather for Roundtable Consensus Regarding Multiple Myeloma Related Disease
Date:2/23/2009

LOS ANGELES, Feb. 23 /PRNewswire-USNewswire/ -- On Wednesday, February 25, 2009, the Institute for Myeloma and Bone Cancer Research (IMBCR) will host a roundtable discussion bringing leading scientists in the field of cancer research together to discuss monoclonal gammopathy of undetermined significance (MGUS). The event is being cochaired by James R. Berenson, MD, who is Medical and Scientific Director at the IMBCR and Robert A. Kyle, MD, who is Professor of Medicine at the Mayo Clinic.

The goal of this roundtable discussion is to develop a consensus statement to be published in a major medical journal related to all aspects regarding the evaluation, follow-up and treatment of patients at risk for MGUS and its associated bone loss and fracture.

Topics for discussion include: addressing important issues such as which patients should be screened and how often; specific types of work-ups for patients; diagnostic testing for evaluation of bone disease; treatment measures for patients with significant bone loss and fractures; and other potential studies to be conducted for this disease population.

The event will take place February 25th at the Marriott Wardman Park Hotel just prior to the 12th Annual International Myeloma Workshop in Washington, D.C.

MGUS is a common condition in which a monoclonal paraprotein is detected in the blood and/or urine but these patients do not have a malignant disorder associated with the presence of this protein. More than 3% of individuals over 50 years of age and 5% of individuals over 70 have this condition. Studies show these individuals have an increased risk to develop cancers including myeloma and lymphoma with a very high risk of bone loss and fractures. There is no current consensus on the work-up, follow-up and treatment of patients with MGUS.

The Institute for Myeloma and Bone Cancer Research is a non-profit organization headquartered in Los Angeles, California. IMBCR is the only independent cancer research institute working to find improved treatment and ultimately a cure for multiple myeloma and other blood cancers. Drs. Berenson, Kyle and the IMBCR research team have been published in most major oncology journals such as the New England Journal of Medicine, Mayo Clinic Proceedings, BLOOD, Journal of Clinical Oncology, Science, Proceedings of the National Academy of Sciences, Cancer, Clinical Cancer Research, Clinical Lymphoma and Myeloma, Nature, Oncogene and the British Journal of Haematology. www.imbcr.org

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

James R. Berenson, MD

https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=86038


'/>"/>
SOURCE Institute for Myeloma and Bone Cancer Research
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. International study strengthens case for daily calcium pill
2. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
3. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
4. LCA Hails International Investigators Studying Lung Cancer
5. Arrow International Urges Shareholders To Vote for Approval of the $45.50 Teleflex Inc. Merger and for the Current Board of Directors
6. PRA International Adds Dr. Susan Stansfield as Executive Vice President
7. Medical Services International Maintains Pace in Second Quarter
8. Clarity Imaging International, Inc. Rolls Out Mobile DEXA Program
9. International Gateway Insurance Brokers Partners With MEDILINQ
10. Tulane University to receive $14M for international HIV/AIDS program
11. International Database Seeks to Boost Treatment of Altitude Sickness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2017)... ... August 21, 2017 , ... Marathon ... all over the country. , Outdoor running increases exposure to ultraviolet radiation, a ... increased risk of melanoma, and only half may be adequately protecting themselves with ...
(Date:8/21/2017)... (PRWEB) , ... August 21, 2017 , ... San Diego ... ) health care reform plan, has announced his candidacy for the 52nd Congressional District ... and shared in America’s Promise. Coming to this country at age eleven after suffering ...
(Date:8/20/2017)... ... ... State Farm Neighborhood Assist® has named The Southern Maryland Team Anti-Bullying Program ... initiative wins, Gals Lead – Dream Queen Foundation’s signature teen girl program to help ... Calvert and Charles Counties. The program could potentially impact nearly 17,500 female students (49.4 ...
(Date:8/19/2017)... MD (PRWEB) , ... August 18, 2017 , ... ... and Drug Administration Reauthorization Act of 2017, legislation that provides for greater public ... mild to moderate hearing loss to access OTC hearing aids without being seen ...
(Date:8/19/2017)... ... August 19, 2017 , ... Parker at Stonegate, an assisted ... passionate employees, caregivers, volunteers, thought leaders, researchers, educators and partners leading the way ... time to refresh the carpeting with the goal of maintaining the same precise ...
Breaking Medicine News(10 mins):
(Date:8/2/2017)... CaryRx, a next-generation full-service pharmacy, has announced the ... in the Washington D.C. metropolitan area. ... delivery of medications through the convenience of its patient-friendly mobile ... within one hour to any location in D.C. ... invaluable service to Washington D.C. ," says ...
(Date:7/31/2017)... Surgical, developer of ground breaking surgical navigation technologies, announced today ... support its strategic sales plan in Maryland ... Surgical has entered into an exclusive sales representative agreement with ... those markets. ... Spartan Medical Purchases 7D Surgical Technology ...
(Date:7/27/2017)...  West Pharmaceutical Services, Inc. (NYSE: WST ... 2017 and updated financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, ... Net sales at constant currency (organic) grew by 3.9%. ... compared to $0.60 in the prior-year quarter. Second-quarter 2017 ...
Breaking Medicine Technology: